Related Experiment Videos
[In vitro and clinical studies of MRSA infections in compromised hosts]
T Kawayama1, N Tokunaga, T Yokoyama
1First Department of Internal Medicine, Kurume University, Japan.
Abstract:
From January to December 1991, 47 clinical cases in when methicillin-resistant Staphylococcus aureus (MRSA) strains were isolate were investigated at our internal medicine ward. The MRSA infection rate was 57.4% (27/47). The mortality due to MRSA bacteremia was 75.0% (9/12) and that due to MRSA pneumonia was 57.1% (4/7). We think that MRSA infections must be treated by multiple antibiotics. At out institution, most of the patients were given a combination therapy of imipenem + fosfomycin or imipenemt + mynocycline. Although in vitro the MICs of imipenem did not show excellent activity against MRSA strains, in vivo these combination therapy including imipenem showed excellent activity against MRSA infections. We think that this result was due to the additive effect of the two drug combination. We determined the MICs of single antibiotics against MRSA strains. Most of the MRSA strains were sensitive to minocycline and arbekacin. All MRSA strains were sensitive to vancomycin we think that vancomycin is a highly useful drug to combat MRSA infection.
Insights
Methicillin-resistant Staphylococcus aureus (MRSA) infections are a significant concern, with combination therapies including imipenem showing in vivo efficacy. Vancomycin is highly effective against MRSA strains.
Area of Science:
- Infectious Diseases
- Microbiology
- Pharmacology
Context:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant threat in hospital settings.
- Investigated 47 clinical cases of MRSA infections between January and December 1991.
- MRSA infection rate was 57.4%, with high mortality for bacteremia (75%) and pneumonia (57.1%).
Purpose:
- To evaluate the efficacy of combination antibiotic therapies against MRSA infections.
- To determine the in vitro and in vivo activity of various antibiotics against MRSA strains.
- To identify effective treatment strategies for MRSA infections.
Summary:
- Combination therapy including imipenem with fosfomycin or minocycline demonstrated excellent in vivo activity against MRSA infections, despite lower in vitro MICs for imipenem.
- This suggests an additive effect between the combined drugs.
- Vancomycin showed high sensitivity across all tested MRSA strains, indicating its utility in combating MRSA infections. Minocycline and arbekacin were also effective against most strains.
Impact:
- Highlights the potential of combination antibiotic therapy in managing severe MRSA infections.
- Identifies vancomycin as a crucial drug for MRSA treatment.
- Provides insights into effective antimicrobial strategies for drug-resistant bacteria.